Literature DB >> 22461828

Prevalence of osteoporosis and vertebral fractures in acromegalic patients.

Giuseppina Padova1, Graziella Borzì, Laura Incorvaia, Guido Siciliano, Valentina Migliorino, Mario Vetri, Patrizia Tita.   

Abstract

Growth Hormone (GH) and Insulin-like Growth Factor (IGF-1) stimulate proliferation, differentiation and extracellular matrix production in osteoblastic cells. GH and IGF-1 also stimulate recruitment and bone resorption activity in osteoclastic cells. A chronic systemic GH and IGF-1 excess produces an increased bone turn over in acromegalic patients (pts). Osteoporosis, joint alterations and bone deformities have a great clinical relevance in acromegalic pts and favour mortality and morbility. In the present study we evaluate the still unclear GH/IGF-1 activity on bone, Bone Mineral Density (BMD) and risk of osteoporotic Vertebral Fractures (VF), in relation to gender and gonadal status in acromegalic pts.Twenty acromegalic pts (12 F, 8 M) ranging 26-64 years were studied. Four pts were hypogonadic (1 F, 3 M), seven women were in post-menopause (PM) and four women eugonadic. The disease was active in twelve pts and inactive in eight pts. Serum and urinary 24/hrs calcium and phosphate and serum PTH, bone formation (P1NP) and resorption (beta-CTX) markers were assayed. BMD was measured using dual energy X ray absorptiometry (DXA) at the lumbar spine and femoral neck and bone quantitative ultrasonography (QUS) at phalanges. Osteoporotic VF were assessed by antero-posterior and lateral x-ray examinations of the thoracic and lumbar spine.Serum IGF-1, calcium and phosphate and 24-hours urinary calcium were significantly higher in pts with active disease in respect to pts with inactive disease. BMD was reduced in more of 50% of pts, in each skeletal sites measured. Z-score values were lower in males than in females. VF prevalence was 39% (43% in women, 57% in men). Fractured and non-fractured pts were not significantly different for BMD, T-score and Z-score.In conclusion, VF are frequent in acromegaly and, even mild and asymptomatic, play an important role on life quality and survival, already decreased in acromegalic pts. DXA and QUS methods are not sufficient for identifying pts at risk for fracture, due to the many possible interferences (bone deformities, osteoarthritis, joint rigidity and soft tissue tickening), since BMD is just one determinant of bone fracture. In the screening of acromegalic complications, it is necessary to perform a radiographic study of the spine at the time of diagnosis and during follow up.

Entities:  

Keywords:  acromegaly; osteoporosis

Year:  2011        PMID: 22461828      PMCID: PMC3279059     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  17 in total

1.  Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients.

Authors:  T Ueland; S L Fougner; K Godang; T Schreiner; J Bollerslev
Journal:  Eur J Endocrinol       Date:  2006-11       Impact factor: 6.664

2.  Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women.

Authors:  Stefania Bonadonna; Gherardo Mazziotti; Monica Nuzzo; Antonio Bianchi; Alessandra Fusco; Laura De Marinis; Andrea Giustina
Journal:  J Bone Miner Res       Date:  2005-06-06       Impact factor: 6.741

3.  Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients.

Authors:  H D White; A M Ahmad; B H Durham; A Patwala; P Whittingham; W D Fraser; J P Vora
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

4.  The effects of growth hormone on cortical and cancellous bone.

Authors:  T T Andreassen; H Oxlund
Journal:  J Musculoskelet Neuronal Interact       Date:  2001-09       Impact factor: 2.041

Review 5.  GH/IGF-I and bone resorption in vivo and in vitro.

Authors:  Thor Ueland
Journal:  Eur J Endocrinol       Date:  2005-03       Impact factor: 6.664

6.  Prevalence of vertebral fractures in men with acromegaly.

Authors:  Gherardo Mazziotti; Antonio Bianchi; Stefania Bonadonna; Vincenzo Cimino; Ilaria Patelli; Alessandra Fusco; Alfredo Pontecorvi; Laura De Marinis; Andrea Giustina
Journal:  J Clin Endocrinol Metab       Date:  2008-09-30       Impact factor: 5.958

7.  Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.

Authors:  C Parkinson; M Kassem; L Heickendorff; A Flyvbjerg; P J Trainer
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

8.  Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status.

Authors:  Alfredo Scillitani; Claudia Battista; Iacopo Chiodini; Vincenzo Carnevale; Saverio Fusilli; Enrica Ciccarelli; Massimo Terzolo; Giuseppe Oppizzi; Maura Arosio; Maurizio Gasperi; Giorgio Arnaldi; Annamaria Colao; Roberto Baldelli; Maria Rosaria Ghiggi; Daniela Gaia; Carolina Di Somma; Vincenzo Trischitta; Antonio Liuzzi
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

Review 9.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

10.  Biochemical assessment of bone formation and resorption in acromegaly.

Authors:  S Ezzat; S Melmed; D Endres; D R Eyre; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958

View more
  14 in total

1.  The acromegalic spine: fractures, deformities and spinopelvic balance.

Authors:  Bruno de Azevedo Oliveira; Bruna Araujo; Tainá Mafalda Dos Santos; Bárbara Roberta Ongaratti; Carolina Garcia Soares Leães Rech; Nelson Pires Ferreira; Júlia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

Review 2.  Acromegalic osteopathy.

Authors:  G Mazziotti; F Maffezzoni; S Frara; A Giustina
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  The effects of high serum growth hormone and IGF-1 levels on bone mineral density in acromegaly.

Authors:  S Tuzcu; Ş A Durmaz; A Carlıoğlu; Z Demircan; A Tuzcu; C Beyaz; A Tay
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

Review 4.  Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Authors:  Cláudia Ribeiro de Moura; Sara Campos Lopes; Ana Margarida Monteiro
Journal:  Pituitary       Date:  2022-07-22       Impact factor: 3.599

5.  Is every joint symptom related to acromegaly?

Authors:  Gonca Örük; Figen Tarhan; Mehmet Argın; Mustafa Özmen
Journal:  Endocrine       Date:  2012-08-21       Impact factor: 3.633

6.  Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength.

Authors:  S V Lim; M Marenzana; M Hopkinson; E O List; J J Kopchick; M Pereira; B Javaheri; J P Roux; P Chavassieux; M Korbonits; C Chenu
Journal:  Endocrinology       Date:  2015-02-03       Impact factor: 4.736

Review 7.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

8.  Trabecular Bone Score and Osteoprotegerin as Useful Tools in the Assessment of Bone Deterioration in Acromegaly.

Authors:  Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Joanna Syrycka; Agnieszka Zembska; Justyna Kuliczkowska-Płaksej; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-21       Impact factor: 6.055

Review 9.  Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis.

Authors:  Vittorio Locatelli; Vittorio E Bianchi
Journal:  Int J Endocrinol       Date:  2014-07-23       Impact factor: 3.257

10.  Osteoarticular changes in acromegaly.

Authors:  Zdenko Killinger; Martin Kužma; Lenka Sterančáková; Juraj Payer
Journal:  Int J Endocrinol       Date:  2012-09-12       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.